VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025

VYNE Therapeutics Inc.

2025-Q1 EPS reported -$0.20 revenue$202,000

Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.
R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.
Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.
Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.
Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.